The Fourth Annual Corporate Compliance & Transparency in the Pharmaceutical Industry, presented by Fleming Europe, will take place February 24 – 25, 2016 in Zurich, Switzerland.
The two-day event is packed with speakers who will aim to provide attendees with: an update on the implementation of the Disclosure Code and the first outcomes and how to evaluate your implementation process; tips on how to unravel compliance challenges relating to data privacy; an understanding of how to optimize interactions with health care providers and health care organizations through a fully compliant and transparent strategy to obtain consent; and information on compliance implications and concerns for merging corporate cultures.
On Wednesday, February 24, 2016, the day will begin with an update on implementation of the disclosure code from the European Federation of Pharmaceutical Industries and Associations. Richard Bergstrom of the EFPIA will discuss do’s and don’t when implementing EFPIA’s codes, what will happen once the data is disclosed, and challenges relating to external communication and specific countries relating to disclosure. The morning continues with three separate discussions about transparency: a panel on transparency obligations; a panel on local perspectives – disclosure and transparency lessons learned; and keynote on data privacy and transparency requirements under the EU Data Protection Directive. Following lunch, the afternoon brings more panels and discussions, including a talk on how to determine fair market value, a keynote from Adrien Van Den Hoven of European Generic and Biosimilars Medicine Association, and a case study on communication and relationships with health care providers. Wednesday ends with a networking cocktail reception.
Thursday, February 25, 2016, begins with a panel on best practices: compliance program structure and effectiveness, with speakers from Sandoz, Acino Pharma AG, and Biogen. Following the panel, Nina Stoeckel from Merck KGaA will speak about how critical team structure is to success. Marit Pless will conclude the morning session by providing a roadmap for conducting internal investigations. The afternoon will be spent hearing from representatives from AstraZeneca and Johnson & Johnson on topics such as compliance and risk assessment and how to organize an approach for communicating, training, and monitoring third parties.
If you’re interested in attending the Fourth Annual Corporate Compliance & Transparency in the Pharmaceutical Industry, you can register here.